IP Verse

Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or Hyperglycemia

Patent No. EP2396005 (titled "Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or Hyperglycemia") was filed by Boehringer Ingelheim on Feb 11, 2010. The application was issued on Nov 26, 2025.

Patent Summary

The SGLT2 inhibitor 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene is used in a method to improve glycemic control in patients with type 2 diabetes mellitus. The treatment consists of a pharmaceutical composition administered orally as a monotherapy. The specific dosage strength is 10 mg, administered once daily. The inhibitor functions by decreasing the renal reuptake threshold of glucose, thereby increasing glucose excretion in urine to lower blood glucose concentrations. Broadly, the inhibitor is indicated for treating metabolic disorders (including type 1 and 2 diabetes, obesity, and metabolic syndrome), preventing diabetes-related micro- and macrovascular complications, reducing body weight, restoring pancreatic beta-cell functionality, treating hyperuricemia, and managing hyponatremia or kidney stones.

Patent Family

Patent Family

Patent Oppositions (20)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ADALVOAug 26, 2026SLAVIK
CAMULONAug 26, 2026REDDIE & GROSE
ELKINGTON AND FIFEAug 26, 2026ELKINGTON AND FIFE
ZENTIVA KSAug 26, 2026REDDIE & GROSE
DEVA HOLDING ANONIM SIRKETIAug 25, 2026-
EGISAug 25, 2026MAIWALD PATENT- UND RECHTSANWALTSGESELLSCHAFT MBH
HGFAug 25, 2026HARRISON GODDARD FOOTE
SANDOZAug 25, 2026ELKINGTON AND FIFE
STADA ARZNEIMITTELAug 25, 2026KERNEBECK
BETAPHARM ARZNEIMITTELAug 24, 2026MAIWALD PATENT- UND RECHTSANWALTSGESELLSCHAFT MBH
BÃœLLE DR., JANAug 24, 2026KUTZENBERGER WOLFF & PARTNER
KRKAAug 24, 2026KUTZENBERGER WOLFF & PARTNER
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETIAug 20, 2026SONNENHAUSER
TEVA PHARMACEUTICAL INDUSTRIES LTDAug 13, 2026VON KAUFFMANN
BARDEHLE PAGENBERGAug 10, 2026BARDEHLE PAGENBERG SL
BRAND MURRAY FULLERAug 3, 2026BRAND MURRAY FULLER
BRAND MURRAY FULLER SERVICESAug 3, 2026BRAND MURRAY FULLER
GALENICUM HEALTH SLUJul 28, 2026GALENICUM HEALTH SLU
GENERICS UKJul 24, 2026TER MEER STEINMEISTER & PARTNER GBR
GENERICS UKJul 24, 2026TER MEER UND PARTNER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2396005

BOEHRINGER INGELHEIM
Application Number
EP10703287A
Filing Date
Feb 11, 2010
Status
Granted And Under Opposition
Oct 24, 2025
Publication Date
Nov 26, 2025
External Links
Slate, Register , Google Patents